Project Grant R01AR087742
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of California, San Francisco $545,808 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research to develop matrix-modifying therapies that increase cartilage endplate permeability and improve nutrient transport to spinal disc cells. The project addresses the mechanism underlying disc degeneration by investigating...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $117,426 to the University of California, San Diego on June 18, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a noninvasive MRI method for assessing bone quality in type 2 diabetes patients. The project develops an ultrashort echo time quantitative magnetization transfer (UTE-QMT) MRI technique to measure collagen crosslinking in cortical bone, a bone quality...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Southern California Institute For Research And Education $337,072 on June 19, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research into the cellular and molecular mechanisms of CCDC120-associated osteopetrosis, a novel form of X-linked osteopetrosis. The research examines how loss of the CCDC120 gene and its binding partner CYTOHESIN-2 in osteoclast...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Duke University $124,875 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate muscle-to-bone communication during fracture repair and musculoskeletal regeneration. The research identifies pro-regenerative signals from injured muscle that orchestrate repair of both bone and muscle tissue. Preliminary findings...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Leland Stanford Junior University $200,478 on September 10, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research into the origin and fate of adipo-CAR (CXCL12-abundant reticular) cells in PTH1R-OSXKO mice. The work addresses how parathyroid hormone receptor signaling influences mesenchymal stem cell lineage allocation between bone-forming...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of California, San Francisco $347,760 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct computational discovery of precision therapeutics for hidradenitis suppurativa, a chronic systemic inflammatory skin disorder. Work comprises three aims: identifying immunologic signatures and pathways in HS...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Johns Hopkins University $671,214 on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate somatosensory nerve regulation of fracture repair. The research focuses on the role of tropomyosin receptor kinase A (TrkA)-positive sensory neurons in bone healing, specifically examining how these neurons regulate fracture repair through the release of...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of California at Riverside $224,100 on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate epigenetic factors controlling epidermal stem cell longevity in adult skin. The research examines how epigenetic regulators, specifically polycomb repressive complexes, function in hair follicle stem cells and interfollicular...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The University of Texas Health Science Center at San Antonio $496,963 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the osteocyte interactome's role in bone mechanotransduction and osteogenesis. The research elucidates how osteocytes—the primary mechanosensory cells in bone—coordinate bone remodeling through a...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of California, Los Angeles $493,148 on September 3, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to characterize mechanisms of intra-epithelial migration in the developing epidermis. The project uses live imaging of developing zebrafish to investigate how specialized cell types arising from basal epidermal cells—specifically...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of California, San Francisco $448,563 on September 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) for an ancillary study investigating systemic bone loss mechanisms following fracture. UCSF will conduct multimodal analysis of circulating cells and factors in blood samples collected from fracture patients at multiple timepoints post-injury. The research employs single-cell RNA sequencing of circulating leukocytes and osteoclast precursors to measure gene expression at individual cell resolution, proteomic analysis of serum samples to characterize whole-tissue protein expression, and metabolomic analysis of serum samples to identify small molecules present in blood following fracture. The study will apply multimodal predictive modeling to identify key biomarkers and biological mechanisms driving post-fracture systemic bone loss. The ancillary study leverages an ongoing parent longitudinal study that uses clinical imaging to characterize the time course and magnitude of systemic bone loss and recovery following humerus fracture. The work is performed in San Francisco, California, with a period of performance through June 30, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $448.6k | 9/3/26 |